Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree.
I even made that mistake at the end of the day today when I left my out of office voicemail since I am out the rest of the week.
Here it is:
Risk: The BoA analyst and I spoke with before my departure yesterday (was in your meeting), he said between today and Monday afternoon, the partnership would be announced. He doesn't think it's Quest in particular that they're talking about with this, in fairness, that would contradict what I have heard. He's not a bio guy, just a finance guy. He also said in their docs that the uplist is planned for July app process, which at that time would be filed with the SEC. He is confident BoA will buy, he said it is in fact in the open market. I was curious about that and the only way they'd do buys outside of that is if the company offered a mixed shelf or placement, he said they already have 20m secured, so getting better prices on the stock isn't an option for most capital venture and banks right now, Gerald has no reason to dilute to gain sales. That makes sense, forgot about the 20m line of cash until he mentioned it. That ought to prevent severe dilution going forward and is probably what's holding the pps up a little right now in my best guess. We shall see, Gerald was very happy, full of conviction and he reaffirmed everything I would like to hear. They ARE going after Type 1, probably not with Urano, U-Mass seems to be the choice of interest, I will state again to watch Denise Faustman, they need to stop the attack, not just reverse cell damage, she is stopping the attack with BCG. All safe and effective treatments when combined, could be a powerhouse in Type 1 research and cur
More importantly, this is happening without any news!
Look for another run up once .085 is broke.
Low, put AMBS back on radar if not already. An updates chart analysis would be great.
To me it looks like if continuation occurs Monday we have a breakout mode in play.
Trust me, I am not excited about these levels as I agree with your valuations. It is good to remind those watching from afar that support levels are in place for a proper bounce out of this channel. Additionally, not everyone is watching the level 2 to see a $40k bid being placed once it is outbid. I think it is good for everyone to see the buying support and confidence, especially going into the close.
Thanks again for the rundown in valuation. Those who don't price in future earnings will be left chasing IMO. Next week is setting up to be a good week TA wise and with any news will be a huge bounce.
Thanks again
Tsuguy
Huge bid just posted
AMBS broke out of the channel and with good volume. All indicators for chart looks for continuation breakout next week.
AMBS closing strong and above channel. Breakout is set for next week.
AMBS breakout from channel.
AMBS broke out of channel today and ready to run next week.
Breakout alert on AMBS.
AMBS just broke out. Check it out.
AMBS breakout this morning. Check out the chart!
WSGI Future
We are committed to moving WSGI forward by growing GTC's business and accelerating the development and commercialization of the Argus One. As a result of the above transactions, WSGI now has capital to run its business in the near term and has the ability for future growth (interesting statement...why didn't they say operations) by accessing additional capital pursuant to the term sheet once an effective registration statement is on file with the SEC, assuming the other conditions of the term sheet are satisfied. The Company also plans on working with the consultants to strengthen the Company's balance sheet through the ongoing clean up of legacy issues such that WSGI will hopefully be able to receive additional funding on satisfactory terms in the future. The consultants will also be working with the Company to identify potential companies to acquire that will advance one or more of the Company's business lines. The consultants WSGI will be receiving advice and guidance from are a group of experts and investors with a proven track record in restructuring and recapitalizing companies in the small- and mid-cap space. We are honored and excited to begin working with our new investors and advisors and look forward to transitioning the results of our soon to be growing business and the improvements in our balance sheet into a reflection in our share price.
Finally, the shares of DAC received by the Company as purchase price in the sale of LTAS are also now a significant asset of the Company and could become more valuable based on the value of the DAC common stock going forward, which will be partly a result of the success of our LTAS business acquired by DAC (what else is DAC going to be doing or have to offer?). WSGI now also has capital to invest to accelerate the development and commercialization of the Argus One and expand the customer base for GTC into additional markets.
We appreciate your continued support as we focus on our core businesses and continue our strategic business transformation of WSGI. We look forward to sharing our future success with you, our shareholders (oh please do share).
Ty for bringing me up to speed...eom
After transfer to the Ohio LTA UAS Consortium, the Argus One was immediately dispatched to the Electronic Warfare Associates Engineering Facility in Fairmont, West Virginia. There it underwent static testing, inspection and design assessment. When this was completed, the propulsion and avionics pod of the Argus One was separated from the envelope assembly for installation at the Center for UAV Exploitation (CUE) in Dayton, Ohio that is co-located with the United States Air Force (USAF) Rapid Prototyping Center. The CUE is a supporting partner of the Consortium and this is presently the only commercial product under testing and development within the facility. Beside avionics and flight control testing, the pod will also be evaluated there for the possible installation of a hybrid propulsion system similar to types presently under development by the USAF.
The envelope assembly of the Argus One will be housed with the Unmanned Systems Innovation Center (USIC) at Springfield Beckley Airport near Dayton, Ohio. Two Argus One demos are planned at the USIC in 2014 in conjunction with the Ohio/Indiana UAS Center and Test Complex. One demo will highlight the new ducted fan/vectored thrust propulsion system presently under development and the other will be for congressional staff. We anticipate Certificates of Authorization will be secured for these events through the Ohio/Indiana UAS Center and Test Complex, allowing for untethered operation.
https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=tC1rces8D7qmgJOnpz4hPA%253d%253d&nt7=0
Drone Aviation Corp link above and the holding company below:
https://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=izmopMdvnDGmW61MRMgxdw%253d%253d&nt7=0
droneaviationcorp.com website reverts back to wsgi.com
I find that very interesting.
Maybe someone can look them up to see who holds the hosting info.
Risk, I think it is difficult for many to understand the importance of implementing a strong 'business foundation' before commercialization occurs. We are still a startup bio. We have no revenue and only expenses to this point. However, much is to be gained by establishing this foundation properly prior to launch. Let's be clear...financially, I think we only have one shot to successfully launch this 1st product. We can't afford for it to go wrong in any way.
Business's that don't properly plan, often fail. If we are not ready for this launch, we will also likely fail. The stock price deflation drag would also be a detriment to all of our other products in the pipeline through private equity dilution.
This is also partly why GC has established a holding company in my opinion to keep winners and failures separate for future growth potential. From the presentation yesterday, I think there are other opportunities being sought out to introduce into the pipeline. This may not be near term as in weeks, but months away. Just my opinion.
Absolutely correct, sir. He also mentioned manufacturing facilities 'are being' and then changed his wording to 'will be in place' over the coming months. That is not exact quotes but close to his speak. Did anyone else happen to catch that as well?
Was at the sox v. Cubs game last night BH. I assume u r Chicago guy yourself with your handle. Back on the road this afternoon to Indy after some meetings.
I, like you, don't care about the trading pattern of anyone else. In fact, this stock presents great opportunity for 'traders' and follows the resistance levels well.
I do agree also on the point that those who sell will likely be the ones buying at a later time, whether it is chasing news or on low side floor support lines. This is simply what makes the market. The more predictable a stock follows a pattern the more of these individuals play it...until the pattern is broken, that is.
Simply put, until something material happens of absolute income generation, I would expect more of the same. We will know we are in breakout mode when more wedge/channel 'traders' jump in on the next breakout. This could happen soon IMO and think this consolidation is actually helping the company and longs.
Think of it this way. With each day we trade at these levels the more people can buy. Each new day also presents another day to introduce AMBS to another 'potential' long holder. The more of these long controlled holders there are the less float for 'traders'...ie the more explosive the breakout will be.
Give it time, my friends. Things are lining up well if one believes what is being built and being told comes true.
These prices are gifts of god, just like the research/products we are invested.
Best of luck to all,
Tsuguy
My take is GC tailored his presentation around lympro and Alzheimer's for a reason. He was very articulate to mention many family's were invested in Alzheimer cures already, but AMBS was there to assist in making their philanthropy/investment come to fruition.
He was very direct in that point, and I don't think it was by accident. A good salesman tailors his presentation to the needs/desires of each group. I think he did just that, and articulated it well.
I am glad someone else heard that too. Just making sure I wasn't hearing something different.
re: "One new thing that was a positive from Gerald today was that he said we'd gotten a "functionality test" completed for Retinitis and the results were positive. That signals that we'll be moving Retinitis forward as fast as possible!! "
Watch the Cavendish Health Forum here:
http://webtv.un.org/live-now/watch/global-health-impact-forum/2730069554001/
AMBS presents at 11:30 est
Gerald Commissiong (@G_Commish) tweeted at 6:21am - 7 May 14:
#cavendishhealth #cavendishglobal #C4CT Presentation today at 11:30am. $AMBS (
)#cavendishhealth #cavendishglobal #C4CT Presentation today at 11:30am. $AMBS
— Gerald Commissiong (@G_Commish) May 7, 2014
Follow the Cavendish Health Forum here:
https://twitter.com/search?q=%23CavendishHealth&src=hash
Live TV of the presentations:
http://webtv.un.org/live-now/watch/global-health-impact-forum/2730069554001/
This many highly qualified candidates don't sign on to a debt ridden early stage bio company if there is not something material to hang their career hat on. Let's refresh ourselves of just the management team:
Robert Farrell, J.D.
Chief Financial Officer
Robert Farrell, J.D.
Mr. Farrell served as Chief Financial Officer of Titan Pharmaceuticals from 1996 to 2008, and as President and CEO from 2008 to 2010. During his tenure at Titan Mr. Farrell was responsible for all SEC filings, fund raising, financial and tax planning strategies, mergers & acquisitions, corporate partnerships, licensing transactions and financial operations, where he raised over $390M via public equity and non-dilutive financings, including seven corporate partnerships. Mr. Farrell most recently served as CFO at Sanovas, Inc. Mr. Farrell previously served as CFO, Corporate Group Vice President and General Counsel at Fresenius USA and Fresenius Medical Care where he completed 6 corporate partnership and M&A transactions totaling over $4B. Mr. Farrell also previously served as the CFO for the Institute for One World Health in San Francisco and currently serves on the Board of Directors of Prime Genomics, Inc. Mr. Farrell holds a J.D. from the University of California's Hastings School of Law.
Charlotte Keywood, MD
Chief Medical Officer, Therapeutics Division
Charlotte Keywood, MD
Dr. Keywood's experience in the pharmaceutical industry includes running European and US pre- and post-registration clinical development programs across a broad range of therapeutic areas, as well as medical marketing and pharmacovigilance activities. Most recently, she was CMO at Addex Pharma, for ten years, overseeing clinical development of the company's allosteric modulator programs. Dr. Keywood served from 2001 to 2003 as medical director for Axovan, a Swiss biotech company that was acquired by Actelion in 2003. From 1996 to 2001 she was medical director at Vernalis, where she helped bring a new migraine drug, Frova frovatriptan, to the market. From 1991 to 1996 she was medical director of the European subsidiary of US biotechnology company Gensia. Dr Keywood is a cardiologist who completed her post-graduate training at St Thomas' Hospital, London.
Kerry Segal
Head of Business Development
Kerry Segal
Kerry Segal heads-up all Business Development (both buy-side and sell-side) and M&A for Amarantus. Mr. Segal is a 30 year veteran of the biopharmaceutical industry, including very successful stints at J&J, Cephalon, Valeant, Impax and two start-ups. Mr Segal's illustrious career encompasses 22 years of front-line transactional experience during which time he has identified and closed transactions valued in excess of $2.6B and generated non-dilutive capital through partnerships in excess of $270MM. Mr Segal's forte is selectively identifying, pursuing, structuring and closing strategically prudent transactions that generate shareholder value.
Tiffini Clark
Head of Operations and Regulatory Affairs
Tiffini Clark
Ms. Clark brings over 20 years' experience to Amarantus, with over ten years of professional multidisciplinary biotech and pharmaceutical experience, primarily in regulatory, research and development. Ms. Clark recently served as Regulatory Affairs Specialist, Project Management & Regulatory Operations at Pharmacyclics. Previously, she served as Drug Safety Coordinator and Senior Archivist at Johnson & Johnson Pharmaceutical Research & Development. At Pharmacyclics, she was a team member that brought IBRUTINIB from discovery, IND and into Phase 3 clinical development and an integral member of the business development team that executed $975M BTK transaction with Janssen Biotech, Inc. (IBRUTINIB). Ms. Clark was also an integral member of business development team that completed transactions with Novo Nordisk for the Factor VIIa inhibitor, PCI-27483, and the pan-HDAC deal with Les Laboratoires Servier (ABEXINOSTAT). Ms Clark has prepared, submitted and maintained 7 IND's, 1 NDA, several Orphan Drug Applications, FDA meeting packages and Fast Track designations.
F. Randall Grimes
Head of Sponsored Research
F. Randall Grimes
Mr. F. Randall Grimes has more than 20 years of marketing, business development, financial and R&D leadership experience in early stage life science companies. He founded The Randall Group in 2001 to help small to medium-sized technology companies raise funds using state and federal competitive grants. He has garnered over $25 million in non-dilutive capital for clients and employers, including more than $1.5 million for LymPro Test development. Mr. Grimes has previously served as the Vice President of Technology Development at Provista Diagnostics, Inc., Vice President of Operations at RCP Diagnostics, Biomarker Technologies LLC and GW Medical Technologies LLC. Mr. Grimes has authored eight issued patents and has published articles in major technical and trade journals. He holds a B.S from University of Arizona in Material Sciences and Engineering and M.B.A from University of Michigan Business School with an emphasis in new product development and operations management.
Paul Jorgensen
Head of Diagnostics Product Development
Paul Jorgensen
Mr. Jorgensen is a biotechnology executive with over twenty years' experience in the areas of *in-vitro* diagnostics development, validation and manufacturing. He has worked at a number of large biotech and diagnostics firms including Boehringer-Mannheim, Chiron Corporation and the diagnostics division of Bio-Rad Laboratories. In 2000 he helped found and served as Director, Operations for AcroMetrix Corporation which manufactured products for molecular diagnostics and was a pioneer in standardizing viral load assays. The company was sold to Life Technologies in 2009. Most recently Mr. Jorgensen was Director of Development and Laboratory Operations for Tethys Bioscience where he established Tethys' CLIA clinical lab and was responsible for the launch of the company's PreDx Diabetes Risk Score product. Mr. Jorgensen has a degree in Biochemistry and Biophysics from the University of California at Davis.
Mark Wakefield
Head of Clinical Development
Mark Wakefield
Mark Wakefield brings over 15 years of experience to Amarantus across large pharma, vaccines & biotech, of which the last 8+ years were focused on establishing and implementing development strategies, as Head of Clinical Development Operations at Addex Pharma SA (Switzerland), where he was responsible for the execution of multi-national (US & EU) trials. Between 2000 and 2005 he coordinated the public-private partnering between Chiron Vaccines (Italy), Norwegian Institute for Public Health and the New Zealand Ministry of Health and was responsible for the operational execution of the clinical development program, which lead to the successful development and roll-out of MeNZBTM vaccine. From 1998-2000, he was involved in running a large phase 3b cardiovascular study, for Astra, in the Netherlands.
Mr. Wakefield graduated from the University of Amsterdam, where he studied chemistry, with a specialization in biochemistry, in the section Medical Enzymology and Metabolism, E.C. Slater Institute for Biochemical Research, under Prof. J.M. Tager, with an emphasis on the routing of newly synthesized molecules and organelle formation. PhD research on neurotrophic factors during brain development, were done under Dr. R. Balázs, at the Netherlands Institute for Brain Research (now NINS).
We are delighted to note that academic researchers in the United States and Europe have continued to increase our understanding of the potential for MANF to treat Wolfram syndrome and diabetes."
"We are pleased to update the marketplace on the Eltoprazine ADHD program at this time, as we have initiated a review of strategic options for the further development of the program. We believe there is significant value to be unlocked with this program and intend to pursue business development-related transactions that we believe will bolster shareholder value as we prepare to up-list to a national stock exchange." said Gerald Commissiong, President & CEO of Amarantus Bioscience Holdings.
Amarantus gains rights to Eltoprazine worldwide, excluding Asian territories. Amarantus expects to initiate a Phase 2b clinical trial for the treatment of Levadopa-Induced Dyskinesia ("LID") associated with Parkinson's Disease ("PD") in 2014 with Eltoprazine.
The study was conducted at two sites in Sweden where twenty-two patients were given single doses of Eltoprazine and placebo along with a challenge dose of levodopa at each of the 5 treatment visits and assessed for parkinsonian and dyskinesia symptoms over a period of three hours post-treatment.
The 5HT1a/1b pathway is emerging as a key biological pathway in the LID-space, and Eltoprazine is the most advanced drug candidate in this class. Adequately addressing LID in Parkinson's disease would represent a significant improvement to the standard of care for patients worldwide and is a significant commercial opportunity."
At least 4 million people worldwide have Parkinson's disease and 35% exhibit symptoms of LID after 3 or more years of treatment with Levodopa. In addition to LID, 35-50% of PD patients exhibit cognitive dysfunction and 60% exhibit psychiatric disorders, including depression. The potential market opportunity for a drug that could treat LID exceeds $750M annually in the United States alone. With the population aging and average age of diagnosis being 58-62 years, the market growth is significant (2-3%/yr).
San Francisco Calif., and Geneva, Switzerland, May 6, 2014 – Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that it has opened an office in Geneva, Switzerland, in preparation for the establishment of a Swiss affiliate. The main purpose of this office is to facilitate interaction with the European biotechnology, pharmaceutical Research and Development and investment communities.
“As we continue to implement our strategy of building a world class organization, the expansion of the Company into the European market represents an important corporate milestone for the Company,” said Gerald E. Commissiong, President & CEO of Amarantus. “Amarantus is operating in a global environment, where our diagnostic and therapeutic product candidates will have impact around the world. Opening an office in Switzerland positions the Company in proximity to great innovation, as evidenced by neuroscience- and life science focused programs and initiatives such as the Human Brain Project (HBP) and Campus Biotech. HBP is part of the Future and Emerging Technologies Flagship Program, a new initiative launched by the European Commission, and it was recently announced that the HBP research will move to the Campus Biotech site in Geneva. The mission of Campus Biotech is to become a center of excellence and focal point for scientists and entrepreneurs in the life science sector. We believe Geneva and surrounding area will become an important center for innovation in the CNS space in the years ahead, and we are excited about our prospects going forward as a transatlantic company”.
Concurrently, the Company has appointed Mr. Mark Wakefield as Head of Clinical Development across Amarantus’ diagnostic and therapeutic divisions. Mr. Wakefield brings over 15 years of experience, of which the last 8 years focused on establishing and implementing development strategies and operations as Head of Clinical Development Operations at Addex Pharma SA (Switzerland).
“Mr. Wakefield brings significant experience in the Parkinson’s disease Levadopa-Induced Dyskinesia (“PD-LID”) area, having successfully conducted clinical development in this disease space,” said Dr. David Lowe, member of the Amarantus Board of Directors. “As we prepare to interact with US and EU regulatory agencies regarding the proposed design of a Phase2/3 PD LID clinical trial for Eltoprazine, we believe it is important for Amarantus to have a presence in the emerging landscape of CNS biotechnology development in the Geneva area, and believe the opportunity is ripe for an international company such as Amarantus to gain exposure to the Swiss and international research and investment communities as we experience significant growth in the months and years ahead.”
"LymPro far exceeds $500 million annually in the United States alone"
With emphasis on "US alone." We could be looking at a billion dollar revenue a year on LymPro folks!!!
Could this have anything to do with it:
"we believe certain improvements to the LymPro Test ® may be made as a result of their unpublished work (Version 2)."
Can you look up the same for NuroPro
From today's PR:
"in process to re-launch development for our NuroPro diagnostic blood test for Parkinson's disease"
Anyone else watch MJF on Letterman last night. He didn't say AMBS but did say that the blood bio marker test is real close to being a solution:
http://touch.dailymotion.com/video/x1rghf3_david-letterman-michael-j-fox-on-parkinson-s-disease_tv
Not a matter of if, but when!
I agree. When a company brings in someone new at this level, that person wants to verify every piece if info before signing their name.
Everyone here knows that with each day passing, we are closer to big news. This should not be construed at late until it is "late". What has happened this far with this 10k is nothing abnormal. They are acting clear within the filing deadline rules. Further, Gerald knew we were going to be bringing on a new CFO so the extension was already warranted for that reason alone.
Happy days ahead for all in AMBS.
All IMO